Trial Profile
A Multicenter, Randomized, Controlled Study Comparing the Efficacy and Safety of 48 Weeks of 40kD Branched Pegylated Interferon Alfa-2a (PEG-IFN, RO 25-8310) Versus 96 Weeks of PEG-IFN, Alone or in Combination With 100 mg Lamivudine for 48 Weeks in Patients With HBeAg-Negative Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Acronyms PegBeLiver
- Sponsors Roche
- 16 Apr 2010 Actual patient number (129) added as reported by ClinicalTrials.gov.
- 16 Apr 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 31 Mar 2010 Planned end date (Jun 2010) added as reported by ClinicalTrials.gov.